Dylann Cohn-Emery

Articles

Maintenance Olaparib Still Beneficial at 5-Year Mark

March 23, 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.